Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions

• Published in: PloS one Vol. 20; no. 5; p. e0324242
• Main Authors: Poorbaugh, Josh, Sims, Jonathan T., Zhang, Lin, Chang, Ching-Yun, Higgs, Richard E., Nirula, Ajay, Benschop, Robert J.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.05.2025; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Biological markers; Biology and life sciences; Biomarkers; Biomarkers - blood; C-Reactive Protein - analysis; C-Reactive Protein - metabolism; Chemokines; Clinical trials; COVID-19; COVID-19 - blood; COVID-19 - mortality; COVID-19 - therapy; CXCL10 protein; Cytokines; Death; Decisions; Demographics; Demography; Disease transmission; Female; Health aspects; Health care; Hospital systems; Hospitalization; Hospitals; Humans; Identification and classification; Immune response; Infections; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Interleukin 6; Interleukin-6 - blood; Male; Measurement; Medicine and health sciences; Membrane proteins; Middle Aged; Monoclonal antibodies; Mortality; Neutrophils; Patients; Physical Sciences; Prognosis; Proteins; Research and Analysis Methods; Risk groups; SARS-CoV-2; Serum Amyloid P-Component - analysis; Serum Amyloid P-Component - metabolism; Serum proteins; Severe acute respiratory syndrome coronavirus 2; Viral diseases; United States

SARS-CoV-2 infections lead to a wide-range of outcomes from mild or asymptomatic illness to serious complications and death. While many studies have characterized hospitalized SARS-CoV-2 patient immune responses, we were interested in whether serious complications of SARS-CoV-2 infection could be pr...